ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Vertex Pharmaceuticals has received FDA approval for Kalydeco, the first drug to treat the underlying cause of cystic fibrosis rather than just the symptoms. The regulatory green light came nearly three months ahead of FDA’s deadline for making a decision. Kalydeco, which increases the flow of water and salt across cell membranes, is approved to treat only the small subset of the cystic fibrosis population carrying a genetic mutation called G551D. Vertex plans to charge $294,000 annually for the pill, which is taken twice daily.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter